Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.070
Sell
RSI(14)
35.704
Neutral
STOCH(KDJ)(9,3,3)
21.117
Neutral
ATR(14)
0.281
Low Volatility
CCI(14)
-128.448
Sell
Williams %R
82.292
Oversold
TRIX(12,20)
-0.475
Sell
StochRSI(14)
0.000
Sell
Search
Emergent BioSolutions Inc
EBSAdd to Watchlist
7.220USD
-0.050-0.69%
Close 07-31 16:00（ET）Quotes delayed by 15 min
372.53MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.69%
5 Days
-0.55%
1 Month
-12.80%
6 Months
-38.34%
Year to Date
-41.59%
1 Year
+28.24%
Key Figures
7.280Open
7.320High
487.19KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.94%Turnover Ratio
7.260Prev. Close
7.050Low
1.78MTurnover
LossP/E Static
0.72P/B
0.00%Div Yield TTM
-0.63%ROA
14.06052wk High
0.89Volume Ratio
-190.60MNet Profit
52.10MShares
-0.1358EPS TTM
2.34Beta
-1.60%ROE
5.61552wk Low
3.72%Amplitude
53.88%Gross Margin
372.53MMarket Cap
-2.92Reward/Risk
3.85%Risk Rate
TradingKey Stock Score of Emergent BioSolutions Inc
Currency: USD Updated: 2026-07-31Key Insights
Emergent BioSolutions Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Emergent BioSolutions Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Emergent BioSolutions Inc Highlights
StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -53.17, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.30M shares, decreasing 7.38% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 233.33K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+66.20%
Upside Space
Emergent BioSolutions Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+66.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Emergent BioSolutions Inc
EBS
2
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
7.294
Sell
MA10
7.415
Sell
MA20
7.685
Sell
MA50
8.071
Sell
MA100
8.191
Sell
MA200
9.609
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Emergent BioSolutions Inc Info
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOPapa (Joseph C)
Websitehttps://emergentbiosolutions.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52779.700
+401.700 (+0.77%)
28512.000
+351.100 (+1.25%)
7534.600
+59.500 (+0.80%)
14596.000
-153.000 (-1.04%)
63650.000
+798.000 (+1.27%)
6406.900
+41.500 (+0.65%)
78.792
-7.142 (-8.31%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4062.260
+20.830 (+0.52%)
FAQs
What is the current price of Emergent BioSolutions Inc (EBS)?
The current price of Emergent BioSolutions Inc (EBS) is 7.22.
What is the symbol of Emergent BioSolutions Inc?
The ticker symbol of Emergent BioSolutions Inc is EBS.
What is the 52-week high of Emergent BioSolutions Inc?
The 52-week high of Emergent BioSolutions Inc is 14.06.
What is the 52-week low of Emergent BioSolutions Inc?
The 52-week low of Emergent BioSolutions Inc is 5.62.
What is the market capitalization of Emergent BioSolutions Inc?
The market capitalization of Emergent BioSolutions Inc is 372.53M.
Is Emergent BioSolutions Inc (EBS) currently rated as Buy, Hold, or Sell?
According to analysts, Emergent BioSolutions Inc (EBS) has an overall rating of Buy, with a price target of 12.00.
What is the Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS)?
The Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS) is 0.98.